Beam Therapeutics base_Aktie

Beam Therapeutics base_Marktkapitalisierung 2025

Beam Therapeutics base_Marktkapitalisierung

١٫٤٥ number_format_mrd USD

components_StockPageHeader__3

BEAM

components_StockPageHeader__4

US07373V1052

components_StockPageHeader__5

A2PY7P

pages_kennzahlen_[key]_[isin]__30

pages_kennzahlen_[key]_[isin]__70

components_DataTable__24components_DataTable_25
2024٢٫٢٠
2023٢٫٣٨
2022٣٫٦٢
2021٥٫٨٥
2020١٫٤١
2019-
2018-
2017-

Beam Therapeutics Aktienanalyse

pages_kennzahlen_[key]_[isin]__1

Beam Therapeutics Inc. is a leading company in genome editing and was founded in 2018. The company is headquartered in Cambridge, Massachusetts, USA, and aims to develop and bring innovative genome editing technologies to the market. Beam Therapeutics' business model is based on developing groundbreaking technologies that improve and simplify genome editing in living cells. These technologies are used in medicine, agriculture, and other industries to cure diseases, increase crop yields, and improve quality of life. Beam Therapeutics is led by an experienced and competent team composed of leading scientists, engineers, and businesspeople in the industry. The company collaborates closely with industry and academic partners to develop innovative solutions for genome editing. Beam Therapeutics has several business units focused on the development of genome editing technologies and products. One of these business units is the development of CRISPR technologies (Clustered Regularly Interspaced Short Palindromic Repeats), which allow for precise and effective modification of DNA. Beam Therapeutics employs Prime Editors, a new technology that enables the removal, insertion, or replacement of specific DNA sequences. Another important business area for Beam Therapeutics is the development of novel gene therapy products. This involves repairing or removing disease-causing genes in the body to accelerate or even achieve complete recovery. The gene therapy products being developed by Beam Therapeutics have the potential to save lives and provide a long-term solution for certain diseases such as cancer, viral infections, and specific genetic disorders. The company collaborates closely with universities, hospitals, and other institutions to drive the development of gene therapy products. Beam Therapeutics strives to revolutionize the gene therapy industry and improve the treatment of diseases through genome editing. Overall, Beam Therapeutics has an impressive track record and has experienced strong growth in recent years. The company has successfully completed multiple funding rounds to advance its research and development and has hired many talented employees to realize its vision. In summary, Beam Therapeutics is a medical technology company specializing in the development of groundbreaking genome editing technologies and products. The company aims to revolutionize genome editing in medicine, agriculture, and other industries and have a positive impact on people's lives. Beam Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

pages_kennzahlen_[key]_[isin]__85

pages_kennzahlen_[key]_[isin]__77

pages_dividenden_[isin]_index__2

components_kpi_MCAPFaqs_0

components_kpi_MCAPFaqs_1

components_kpi_MCAPFaqs_2

components_kpi_MCAPFaqs_3

components_kpi_MCAPFaqs_4

components_kpi_MCAPFaqs_5

components_kpi_MCAPFaqs_6

components_kpi_MCAPFaqs_7

components_kpi_MCAPFaqs_8

components_kpi_MCAPFaqs_9

components_kpi_MCAPFaqs_10

components_kpi_MCAPFaqs_11

components_kpi_MCAPFaqs_12

components_kpi_MCAPFaqs_13

components_kpi_MCAPFaqs_14

components_kpi_MCAPFaqs_15

components_kpi_MCAPFaqs_16

components_kpi_MCAPFaqs_17

pages_aktie_[isin]_[key]_index_0

pages_aktie_[isin]_[key]_index_1

pages_aktie_[isin]_[key]_index_2

pages_aktie_[isin]_[key]_index_3

pages_aktie_[isin]_[key]_index_4

pages_aktie_[isin]_[key]_index_5

pages_aktie_[isin]_[key]_index_6

pages_aktie_[isin]_[key]_index_7

pages_aktie_[isin]_[key]_index_8

pages_aktie_[isin]_[key]_index_9

pages_aktie_[isin]_[key]_index_10

pages_aktie_[isin]_[key]_index_14

Wann musste ich die Aktien von Beam Therapeutics kaufen, um die vorherige Dividende zu erhalten?

pages_aktie_[isin]_[key]_index_15

pages_aktie_[isin]_[key]_index_16

pages_aktie_[isin]_[key]_index_18

pages_aktie_[isin]_[key]_index_19

pages_aktie_[isin]_[key]_index_20

pages_aktie_[isin]_[key]_index_21

pages_aktie_[isin]_[key]_index_22

components_kpi_Savingsplan_0